Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Authors: Kathleen I. Pritchard
Howard A. Burris
Yoshinori Ito
Hope S. Rugo
Shaker Dakhil
Gabriel N. Hortobagyi
Mario Campone
Tibor Csöszi
José Baselga
Puttisak Puttawibul
Martine Piccart
Daniel Heng
Shinzaburo Noguchi
Vichien Srimuninnimit
Hugues Bourgeois
Antonio Gonzalez Martin
Karen Osborne
Ashok Panneerselvam
Tetiana Taran
Tarek Sahmoud
Michael Gnant
University of Toronto
Sarah Cannon Research Institute
Cancer Institute Hospital of Japan Foundation for Cancer Research
UCSF Helen Diller Family Comprehensive Cancer Center
Cancer Center of Kansas
University of Texas MD Anderson Cancer Center
Centre de Recherche en Cancérologie
Hetenyi Geza County Hospital
Memorial Sloan-Kettering Cancer Center
Prince of Songkla University
Institut Jules Bordet
University of Calgary
Osaka University
Mahidol University
Centre Jean Bernard
MD Anderson Cancer Center, Madrid
Novartis International AG
Novartis Pharmaceuticals Corporation
Medizinische Universitat Wien
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Jan-2013
Citation: Clinical Breast Cancer. Vol.13, No.6 (2013), 421-432
Abstract: Background Postmenopausal women with hormone receptor-positive (HR+) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated that adding everolimus (EVE) to EXE improved progression-free survival (PFS) while maintaining quality of life when compared with EXE alone. Because many women with HR+advanced breast cancer are elderly, the tolerability profile of EVE plus EXE in this population is of interest. Patients and Methods BOLERO-2, a phase III randomized trial, compared EVE (10 mg/d) and placebo (PBO), both plus EXE (25 mg/d), in 724 postmenopausal women with HR+advanced breast cancer recurring/progressing after treatment with NSAIs. Safety and efficacy data in elderly patients are reported at 18-month median follow-up. Results Baseline disease characteristics and treatment histories among the elderly subsets (≥ 65 years, n = 275; ≥ 70 years, n = 164) were generally comparable with younger patients. The addition of EVE to EXE improved PFS regardless of age (hazard ratio, 0.59 [≥ 65 years] and 0.45 [≥ 70 years]). Adverse events (AEs) of special interest (all grades) that occurred more frequently with EVE than with PBO included stomatitis, infections, rash, pneumonitis, and hyperglycemia. Elderly EVE-treated patients had similar incidences of these AEs as did younger patients but had more on-treatment deaths. Conclusion Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR+advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE management are recommended during treatment with EVE in this patient population. © 2013 Elsevier Inc. All rights reserved.
ISSN: 19380666
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.